Trending...
- Roofman USA Expands Roofing Services Across Michigan, Adding Key Locations - 167
- Unicorp and BH Group Select Chasing Creative—Palm Coast Agency—to Lead Growth Marketing for The Ritz-Carlton Residences, Hammock Dunes - 160
- Green Office Partner Named #1 Best Place to Work in Chicago by Crain's for 2025 - 154
MIAMI - Michimich -- First Choice Neurology is proud to announce a groundbreaking partnership with NeuroDiscovery AI (NDAI), a national leader in artificial intelligence, data analytics, and clinical dashboarding for neurology. This strategic collaboration brings cutting-edge AI capabilities to our practice and connects us with a nationwide prestigious network of leading outpatient neurology groups. Together, we are working to transform the future of neurology by advancing research, optimizing patient outcomes, and elevating standards of care.
Through this collaboration, First Choice Neurology joins a national alliance of leading neurology practices committed to driving innovation in patient care with the world's most extensive longitudinal dataset in neurology. Together, we will utilize AI-powered insights to:
Today, we stand at the forefront of neurological research, armed with:
Advancing Care in Key Neurological Areas
Our partnership with NeuroDiscovery AI allows us to focus on several high-impact areas of neurological research and care:
Multiple Sclerosis (MS) - A chronic autoimmune disorder affecting the central nervous system. With the help of NeuroDiscovery AI, our MS specialists can track disease progression, evaluate treatment efficacy, and explore new therapeutic options more effectively than ever before.
More on Michimich.com
"The quality and volume of information that NDAI can garner from our records is outstanding. This collaboration provides us with powerful tools to better understand disease patterns and personalize MS treatment strategies. Levels of magnitude are greater than I thought possible. It's a major leap forward in how we care for our MS patients."
— Dr. Bernard Gran, Neurologist, First Choice Neurology
Parkinson's Disease (PD) - A progressive neurodegenerative disorder that affects movement, cognition, and quality of life. Through data-driven research, we're identifying new biomarkers and refining care models that improve long-term outcomes for Parkinson's patients.
Alzheimer's Disease (AD) - One of the leading outpatient neurology groups treating Alzheimer's and other forms of dementia, First Choice Neurology is at the forefront of clinical care and research. NeuroDiscovery AI will allow us to analyze large-scale data sets, assess the real-world effectiveness of new medications, and contribute to developing novel therapies.
NeuroDiscovery AI offers clinicians and researchers millions of data points to investigate new treatments for neurological disorders. "Let's say you want to evaluate and identify a group of 100 women, between the ages of 50-65, with a maternal history of dementia, and track their development of cognitive decline. NDAI can generate that data in a minute as opposed to weeks or months. Do you wish to assess associated genetic markers? That would take another minute. And to correlate common MRI patterns would take just another minute." Dr. Jeff Gelblum believes that "this new computer technology will revolutionize clinical research and treatment protocols."
More on Michimich.com
— Dr. Jeff Gelblum, Neurologist and national authority on the treatment of Alzheimer's, First Choice Neurology
Frontotemporal Dementia (FTD) - A lesser-known but equally devastating condition that affects personality, behavior, and language. Through our partnership, we aim to accelerate research into early detection and management, contributing to broader efforts in combating all forms of dementia.
Migraine and Headache Disorders - One of the most common neurological disorders, often misunderstood and underdiagnosed. Our migraine specialists are now equipped with enhanced tools to track patient responses to medications and identify patterns that may lead to more effective, personalized treatments.
Autism and Developmental Disorders - Neurodevelopmental conditions like autism require a highly individualized and evidence-based approach. With this partnership, our child neurologists and neuropsychologists will be able to integrate behavioral data and clinical metrics to improve diagnosis and track developmental progress over time.
Looking Ahead
We believe that the future of neurology lies at the intersection of clinical expertise, innovative technology, and collaborative research. Our partnership with NeuroDiscovery AI marks an exciting step forward in our journey to lead that transformation. We look forward to working with them and changing the world, together.
To learn more about First Choice Neurology, visit https://www.fcneurology.net/
To learn more about NeuroDiscovery AI, visit https://neurodiscovery.ai/
Through this collaboration, First Choice Neurology joins a national alliance of leading neurology practices committed to driving innovation in patient care with the world's most extensive longitudinal dataset in neurology. Together, we will utilize AI-powered insights to:
- Revolutionize patient care through AI and extensive medical data
- Monitor treatment outcomes in real-time
- Accelerate research and clinical trials
- Discover new biomarkers & novel targets
- Improve care coordination and efficiency
Today, we stand at the forefront of neurological research, armed with:
- The world's most extensive longitudinal dataset in neurology
- Partnerships with over 470 leading neurology providers across the US
- A comprehensive database consists of multimodal data extracted from 5 M+ patients
- Cutting-edge AI technology to derive meaningful insights from complex data
Advancing Care in Key Neurological Areas
Our partnership with NeuroDiscovery AI allows us to focus on several high-impact areas of neurological research and care:
Multiple Sclerosis (MS) - A chronic autoimmune disorder affecting the central nervous system. With the help of NeuroDiscovery AI, our MS specialists can track disease progression, evaluate treatment efficacy, and explore new therapeutic options more effectively than ever before.
More on Michimich.com
- Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
- Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
- 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
- Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark
- DivX Unveils Major DivX Software Update: Seamless Video Sharing and Customizable Playback Now Available
"The quality and volume of information that NDAI can garner from our records is outstanding. This collaboration provides us with powerful tools to better understand disease patterns and personalize MS treatment strategies. Levels of magnitude are greater than I thought possible. It's a major leap forward in how we care for our MS patients."
— Dr. Bernard Gran, Neurologist, First Choice Neurology
Parkinson's Disease (PD) - A progressive neurodegenerative disorder that affects movement, cognition, and quality of life. Through data-driven research, we're identifying new biomarkers and refining care models that improve long-term outcomes for Parkinson's patients.
Alzheimer's Disease (AD) - One of the leading outpatient neurology groups treating Alzheimer's and other forms of dementia, First Choice Neurology is at the forefront of clinical care and research. NeuroDiscovery AI will allow us to analyze large-scale data sets, assess the real-world effectiveness of new medications, and contribute to developing novel therapies.
NeuroDiscovery AI offers clinicians and researchers millions of data points to investigate new treatments for neurological disorders. "Let's say you want to evaluate and identify a group of 100 women, between the ages of 50-65, with a maternal history of dementia, and track their development of cognitive decline. NDAI can generate that data in a minute as opposed to weeks or months. Do you wish to assess associated genetic markers? That would take another minute. And to correlate common MRI patterns would take just another minute." Dr. Jeff Gelblum believes that "this new computer technology will revolutionize clinical research and treatment protocols."
More on Michimich.com
- Nespolo Mechanical Helps New Mexico Families Save Thousands on Heating Costs This Fall
- Leading Digital Finance Platform YNQTL Launches Revolutionary Web3 Digital Asset Trading Platform
- IDCXS Addresses Crypto Trading Pain Points with 2 Million TPS Processing and Multi-Layer Security Architecture
- Bridging Traditional Finance and Web3 Innovation: BLFCW Announces Strategic Vision for Regulated Web3 Economy
- NKSCX Responds to "Coordinated Smear Campaign" as Anonymous Critics Emerge Following Regulatory Milestones
— Dr. Jeff Gelblum, Neurologist and national authority on the treatment of Alzheimer's, First Choice Neurology
Frontotemporal Dementia (FTD) - A lesser-known but equally devastating condition that affects personality, behavior, and language. Through our partnership, we aim to accelerate research into early detection and management, contributing to broader efforts in combating all forms of dementia.
Migraine and Headache Disorders - One of the most common neurological disorders, often misunderstood and underdiagnosed. Our migraine specialists are now equipped with enhanced tools to track patient responses to medications and identify patterns that may lead to more effective, personalized treatments.
Autism and Developmental Disorders - Neurodevelopmental conditions like autism require a highly individualized and evidence-based approach. With this partnership, our child neurologists and neuropsychologists will be able to integrate behavioral data and clinical metrics to improve diagnosis and track developmental progress over time.
Looking Ahead
We believe that the future of neurology lies at the intersection of clinical expertise, innovative technology, and collaborative research. Our partnership with NeuroDiscovery AI marks an exciting step forward in our journey to lead that transformation. We look forward to working with them and changing the world, together.
To learn more about First Choice Neurology, visit https://www.fcneurology.net/
To learn more about NeuroDiscovery AI, visit https://neurodiscovery.ai/
Source: First Choice Neurology
Filed Under: Health
0 Comments
Latest on Michimich.com
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
- Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
- Cryptocurrency Quarterly Trading Volume Surpasses $15 Trillion Record High as BrazilNex Acknowledges Industry 'Growing Pains' Amid Market Speculation
- AHRFD Initiates Legal Proceedings Against Anwalt.de for Publishing Defamatory and False Content
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
- Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
- NEW power supply release from Kepco Dynatronix - HSP Advanced
- St. Augustine Honors Hispanic Heritage Month
- Vesica Health Receives AUA Guideline Inclusion
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- Spelman College wins 7th annual Moguls in the Making entrepreneurial pitch competition
- Price Right RV Announces Participation in the 36th Annual Fall Detroit RV & Camping Show
- 10xLaw.com Extends Employment Opportunity to Kim Kardashian
- DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies
- CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
- Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
- 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus
- Sarah Meinhart of PSED Law to Present on Estate Planning Strategies in Upcoming Webinar